Lewis Earl

Director Lewis Earl bought 5,000 TGEN shares at $2.52; stock -78.7% from 52-week high, cluster buy pattern with 4 others in 14 days.

Lewis Earl purchased 5,000 shares of TECOGEN at $2.52 on 2026-03-27, bringing his total holdings to 1,011,006 shares. The stock is currently trading at $2.57, down -78.7% from its 52-week high of $12.07 and -31.6% over the past 30 days. At the same-ticker level, Earl's prior buys at TGEN showed strong post-purchase performance: a buy on 2024-11-22 returned +123.9% over 30 days and +218.3% over 90 days, with 3 of his 4 prior measurable TGEN purchases well-timed (positive 90-day returns). However, the company remains unprofitable, reporting net income of $-2,130,947.00 in its latest quarter, though annual revenue growth stands at +19.7%. This purchase is part of a cluster buy pattern, with 4 other insiders buying TGEN within the preceding 14 days, which may indicate coordinated assessment of current valuation relative to business fundamentals, though the depressed stock price and ongoing losses suggest heightened execution risk.

Director Lewis Earl bought 5,000 shares of TGEN at $2.88 (2026-03-26); stock down -78.7% from 52-week high amid cluster buy pattern

Lewis Earl purchased 5,000 shares at $2.88 on 2026-03-26, bringing his total holdings to 1,006,006 shares (+0.5% increase). At the current price of $2.57, the stock has declined -78.7% from its 52-week high and is down -31.6% in the past 30 days. Notably, 4 other insiders also bought within the past 14 days, forming a cluster buy pattern at depressed valuations. Across his same-ticker history at TGEN, 3 of 4 prior measurable buys were well-timed at the 90-day mark, with his most recent buy on 2024-11-22 generating a +218.3% 90-day return. However, the company's fundamentals remain challenged: revenue of $7,183,121.00 with a net loss of $-2,130,947.00 in the latest quarter, though annual revenue growth was +19.7%. The confluence of coordinated insider accumulation at significant lows, combined with positive historical timing pattern at this ticker, suggests insiders view current levels as attractive, but the substantial negative price action and persistent unprofitability warrant attention to execution risks.

TGEN Director Lewis buys 2,000 shares at $0.80; prior buy pattern at this ticker 75% well-timed; stock +100% in 30 days.

LEWIS EARL R purchased 2,000 shares at $0.80 on 2023-10-09, increasing holdings to 637,000 shares. The stock has since risen 100.0% over 30 days and trades at $1.70, 112.5% above the purchase price. Among his five prior TGEN trades, three of four measurable buys produced positive 90-day returns, with outcomes including +24.5%, +12.6%, and +3.1%, suggesting a consistent pattern of buying before subsequent price appreciation at this ticker. However, the company remains unprofitable with net income of $-930,408.00 and only 0.6% annual revenue growth, indicating fundamental headwinds despite the recent price movement. This buy adds to an established accumulation pattern at TGEN, though the strong recent 30-day gain and the company's negative earnings warrant attention to whether price momentum is sustainable.

Director Lewis Earl R purchases 100,000 shares of TGEN at $0.71; holdings increase to 737,000 shares (+15.7%).

Director Lewis Earl R purchased 100,000 shares of TECOGEN INC. at $0.71 on 2024-11-22, increasing his holdings by 15.7% to 737,000 shares total. The stock has appreciated significantly since the purchase, trading at $1.70 current price, representing a 30-day gain of +100.0% and 90-day gain of +89.0%. His prior five trades at TGEN show a mixed pattern: three buys were well-timed at the 90-day mark (returning +12.6%, +24.5%, and +3.1%), though two were poorly timed (returning -16.6% and -4.4% over 90 days). The company remains unprofitable with negative net income of $-930,408.00 in its latest quarter, and annual revenue growth stands at only +0.6%, warranting attention to whether this substantial position increase reflects contrarian conviction or exposure to continued operational challenges.

Director Lewis Earl R bought 10,000 TGEN shares at $0.68 on 2024-07-15 (1.6% addition to 625.0K holding)

Director Lewis Earl R purchased 10,000 shares of Tecogen at $0.68, adding 1.6% to his existing 625,000-share position, for a total value of $6,800.00. The purchase follows a pattern of repeated buying at this ticker—SAME-TICKER HISTORY shows 5 prior trades, including a buy on 2024-05-01 just 2.5 months earlier. However, the measurable outcomes are mixed: his prior buy on 2024-04-24 showed a +17.6% 30-day return, but his 2024-01-24 buy declined -12.2% over 90 days. At the cross-ticker level, his track record across 12 prior buys shows an average 90-day return of -9.5% with a 12.50% win rate, suggesting limited predictive value. Tecogen remains unprofitable (net income $-1.1M in the latest quarter) with minimal revenue growth of +0.6% year-over-year and a market cap of $17.4M; the stock is down -44.4% from its 52-week high of $1.26.

Director Lewis Earl R bought 10,000 shares of TECOGEN at $0.68 on 2024-07-15; holds 625,000 post-transaction

Lewis Earl R purchased 10,000 shares at $0.68, adding 1.6% to his existing 615,000-share position at TGEN. The company is unprofitable with net income of $-1.1M against $6.2M in quarterly revenue, representing minimal annual revenue growth of +0.6%. His cross-ticker track record shows weak returns (avg 30d +0.5%, avg 90d -9.5% with 12.5% win rate), though his prior TGEN purchases include a +17.6% 30-day return on 2024-04-24 and a +12.4% return on 2024-01-23 at the same ticker. The current stock price of $0.76 is -39.7% from the 52-week high of $1.26, though the 30-day trend shows +2.7% and 90-day shows +11.8%. The small transaction size and ongoing operational losses warrant investor scrutiny of both the company's path to profitability and the director's continued accumulation pattern at this depressed valuation stage.